Japan's Nichi-Iko snaps up Sagent for $736M to grow into top global generics firm

Spotlight
Deal

Tokyo-based Nichi-Iko Pharmaceutical will buy Sagent Pharmaceuticals ($SGNT) in a $736 million all-cash deal with management and boards from both sides agreeing to terms aimed at creating a global generics powerhouse.

Nichi-Iko will pay $21.75 for each share of Schaumburg, Illinois-based Sagent, a premium a tad over 40% to the share close price on Friday, July 8 of $15.50, Sagent said in a release on Monday. The transaction is slated to close in the second quarter of the Japanese company's financial year, which started April 1.

The purchase vaults Nichi-Iko out of its sole reliance on the Japanese market, potentially aiding sales in the key U.S. market and wider.

"The transaction enhances Nichi-Iko's platform in the U.S. market to commercialize its biosimilar product pipeline and increase its presence in injectables," according to the press release.

"Through the acquisition, Nichi-Iko will raise its profile in the domestic and international generics market and advance the company's goal of becoming a top 10 global leader in generics."

Nichi-Iko's CEO noted the reach into the U.S. would not include any immediate changes in management and that the transaction was akin to a partnership.

“The U.S. market is a top priority for Nichi-Iko and we believe Sagent is an ideal partner to accelerate our international growth strategy," Yuchi Tamura, CEO for Nichi-Iko said in a statement.

- here's the release from Nichi-Iko (Japanese language)
- and one from Sagent
- and a story from Bloomberg

Related Articles:
Japanese firms eye sale of patent-expired drugs to fund new blockbusters

Read more on

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.